Current Report Filing (8-k)
December 06 2019 - 12:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 5, 2019
AMERICAN BRIVISION (HOLDING) CORPORATION
(Exact name of registrant as specified in
its charter)
Nevada
|
|
333-91436
|
|
26-0014658
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
44370 Old Warm Springs Blvd.
Fremont, CA 94538
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (510) 668-0881
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act: None
Item 7.01 Regulation FD Disclosure
On December 5, 2019, American BriVision
(Holding) Corporation (the “Company”) issued a press release (the “Press Release”) announcing that it initiated
the Phase II Part I clinical trial for ABV-1505 for adult attention-deficit hyperactivity disorder at the University of California,
San Francisco Medical Center.
A copy of the Press Release is being furnished
as Exhibit 99.1 to this current report on Form 8-K. The information contained in this Current Report on Form 8-K shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of the information
in this Current Report on Form 8-K is not intended to, and does not, constitute a representation that such furnishing is required
by Regulation FD or that the information contained in this Current Report on Form 8-K constitutes material investor information
that is not otherwise publicly available.
This Current Report on Form 8-K and exhibits
may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date
of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated
by words or phrases such as “expects,” “should,” “will,” and similar words or phrases. These
statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated
at the date of this Current Report on Form 8-K. The Company disclaims any obligation to, and will not, update any forward-looking
statements to reflect events or circumstances after the date hereof. Investors are cautioned not to rely unduly on forward-looking
statements when evaluating the information presented within.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AMERICAN BRIVISION (HOLDING) CORPORATION
|
|
|
|
Date: December 6, 2019
|
By:
|
/s/
Howard Doong
|
|
Name:
|
Howard Doong
|
|
Title:
|
Chief Executive Officer
|
2